DOCSLIB.ORG

United States Patent (19) 11 Patent Number: 4,780,463 Sunshine Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
United States Patent (19) 11 Patent Number: 4,780,463 Sunshine Et Al United States Patent (19) 11 Patent Number: 4,780,463 Sunshine et al. (45) Date of Patent: Oct. 25, 1988 (54). ANALGESIC, ANTI-INFLAMMATORY AND Ailments of the Musculoskeletal Apparatus), Investiga SKELETAL MUSCLE RELAXANT tion Medica Internactional, pp. 475-478, (1983), and COMPOSITIONS COMPRISING English translation thereof. NON-STEROIDAL ANTI-NFLAMMATORY Socialist Republic of Romania Description of Inven DRUGS AND MUSCULOSKELETAL tion, 82,717, copy of patent and English translation RELAXANTS AND METHODS OF USING thereof. SAME Rego, "Mio-Relaxantes No Tratamento Das Lom 75 Inventors: Abraham Sunshine, New York; balgias Aguda E Da Lombo-Ciaticas Recentes', Mus Eugene M. Laska, Larchmont; cle Relaxants in the Treatment of Acute Lumbalgias Carole E. Siegel, Mamaroneck, all of and Recent Lumbo-Sciatica Cases, Acta N.Y. Reumatologica Portuguesa, II, 2:363-364, (1974), copy of the original and English translation thereof. 73 Assignee: Analgesic Associates, Larchmont, Schror, "Analgetisch-antiphlogistische Therapie Von N.Y. Schmerzzustanden des Bewegungsapparates', Anal 21 Appl. No.: 114,751. gesic-Antiphlogistic Therapy of Locomotor System Pain), Therapiewoche, 28, 5657-5663, (1978), copy of the 22 Filed: Oct. 30, 1987 original and English translation thereof. Schar, "Medikamentose Behandling von Lumboishial Related U.S. Application Data gien', Drug Treatment of the Lumbago-Sciatic Syn 60 Division of Ser. No. 815,502, Jan. 2, 1986, Pat. No. drome, Schweiz. Rundschau Med., (Praxis), vol. 68, No. 4,722,938, which is a continuation of Ser. No. 686,380, 5, pp. 141-142, (Jan. 30, 1979), copy of original article Dec. 26, 1984, abandoned. and English translation thereof. 51) int. Cl.' ..................... A61K 31/19; A61K 31/44; Kolodny and Klipper, "Bone and Joint Diseases in the A61K 3/54; A61K 31/195; A61K 31/205 Elderly', Hospital Practice, pp. 91-101, (Nov., 1976). 52 U.S. Cl. ................................. 514/226.5; 514/279; Nascimento, "Use of an Association Containing an . 514/556; 514/561; 514/570 Analgeisc, a Muscle Relaxant and Vitamin B Complex 58 Field of Search ............... 514/226, 279, 556, 561, in Degenerative Joint Diseases, Extra-Articular Rheu 514A570 matic Ailments and Traumatic Afflications, F med, 56) References Cited (BR), 83(3):361-363, (1981), original article and English translation thereof. U.S. PATENT DOCUMENTS Repschlaeger and McPherson, "Classification, Mecha 4,722,938 2/1988 Sunshine et al. .................... 514/479 nism and Management of Headache', Clinical Phar FOREIGN PATENT DOCUMENTS mary, vol. 3, pp. 139-150, (Mar.-Apr. 1984). 22529 12/1971 France . Primary Examiner-Stanley J. Friedman Attorney, Agent, or Firm-Burns, Doane, Swecker & OTHER PUBLICATIONS Mathis Armas & Valencia, "Eficacia terapeutica de la associa 57 ABSTRACT cion naproxen-carisoprodoi en ciertas enfermedader musculoesqueleticas', Therapeutic Effectiveness of Novel pharmaceutical analgesic, anti-inflammatory and Naproxen-Carisoprodol Association in Certain Muscu skeletal muscle relaxant compositions and methods of loskeletal Disorders, in Investigation Medica Interna using same comprising an analgesically and anti-inflam cional, pp. 350-356, (1983), and English translation matory effective amount of at least one non-steroidal thereof. anti-inflammatory drug other than aspirin, acetamino Goti & Valencia, "Caracterizacion clinica de una nueva phen and phenacetin, in combination with an effectiv asociacion (naproxen-carisoprodol) en padecimientos amount of a skeletal muscle relaxant. del aparato musculoesqueletico', Clinical Description of a New Association (Naproxen.--Carisoprodol) in 14 Claims, No Drawings 4,780,463 1. 2 is a conventional non-narcotic analgesic with anti-in ANALGESIC, ANTI-NFLAMMATORY AND flammatory and antipyretic activity. The most common SKELETAL MUSCLE RELAXANT adverse reactions associated with the use of aspirin in COMPOSITIONS COMPRISING this product have been gastrointestinal, including nau NONSTEROIDAL ANTI-NFLAMMATORY 5 Sea, vomiting, gastritis, occult bleeding, constipation DRUGS AND MUSCULOSKELETAL RELAXANTS and diarrhea. Allergic type reactions associated with AND METHODS OF USING SAME aspirin may also involve the respiratory tract and skin. Another commercial skeletal muscle relaxant formu This application is a divisional, of application Ser. lation is Parafon Forte (R) by McNeil Pharmaceutical. No. 815,502, filed Jan. 2, 1986, U.S. Pat. No. 4,722,938 10 Parafon Forte contains 250 mg chlorzoxazone and 300 which is a continuation of U.S. Ser. No. 686,380 filed mg acetaminophen. Chlorzoxazone is a centrally-acting Dec. 26, 1984, now abandoned. agent which does not directly relax tense skeletal mus cles in man. Acetaminophen, a nonsalicylate analgesic, BACKGROUND OF THE INVENTION is a conventional non-narcotic analgesic with anti 1. Field of the Invention 15 pyretic activity. The present invention relates generally to novel phar Robaxisal (R) by A.H. Robins Company, Inc. is an maceutical compositions of matter comprising one or other commercial muscle relaxant formulation which more non-steroidal anti-inflammatory drugs in combi contains 400 mg methocarbamol and 325 mg aspirin. nation with at least one skeletal muscle relaxant, and to The mechanism of action of methocarbamol in humans methods of using said compositions in the treatment of 20 has not been established, but may be due to general a variety of skeletal muscle disorders including skeletal central nervous system depression. Methocarbamol muscle spasms, certain orthopedic conditions, disk syn does not directly relax tense skeletal muscles in man. dromes, low back pain and the like. Adverse reactions that have been associated with aspi 2. Description of the Prior Art rin in this formulation include: nausea and other gastro Centrally acting skeletal muscle relaxants are gener 25 intestinal discomfort, gastritis, gastric erosion, vomit ally prescribed either as single agents or as components ing, constipation, diarrhea, angioedema, asthma, rash, of combination products. The Food and Drug Adminis pruritis and urticaria. tration has approved indications for these medications Norgesic (E) and Norgesic (R) Forte are commercial as adjuncts to rest and physical therapy for relief of products by Riker Laboratories, Inc. that contain a acute, painful musculoskeletal problems. Clinically, the 30 muscle relaxant, aspirin and caffeine. The specific for mild pain associated with the majority of cases of minor mulation for Norgesic is 25 mg orphenadrine citrate, muscle strains and minor injuries is self limiting. Most 385 mg aspirin and 30 mg caffeine. Norgesic Forte patients usually respond rapidly to rest. An anti-inflam contains 50 mg orphenadrine citrate, 770 mg aspirin and matory drug may be useful when there is considerable 60 mg caffeine. Orphenadrine citrate is 2-dime tissue damage and edema. On the other hand, severe 35 thylaminoethyl 2-methylbenzhydryl ether citrate. The musculoskeletal strains and sprains, trauma, and cervi common side effects and concerns associated with the cal or lumbar radiculopathy as a consequence of degen use of aspirin occur with the use of Norgesic and Nor erative osteoarthritis, herniated disk, spondylitis or lam gesic Forte as well. TABLE I Some Combination Products Containing a Skeletal Muscle Relaxant TYPICAL DOSAGE CONTENTS OF A SINGLE TABLET PRESENTED AS TRADENAME SKELETAL MUSCLE RELAXANT ADDITIONAL INGREDIENTS NO. OF TABLETS SOMA COMPOUND Carisoprodol 200 mg aspirin 325 mg 1-2 SOMA COMPOUND Carisoprodol 200 mg aspirin 325 mg WITH CODEINE codeine PO4. 16 ng 1-2 PARAFON FORTE Corzoxazone 250 mg acetaminophen 300 mg 1-2 ROBAXISAL Methocarbano 400 mg aspirin 325 mg 2 NORGESIC Orphenadrine 25 mg aspirin 385 mg 1-2 Citrate caffeine 30 mg NORGESICFORTE Orphenadrine 50 mg aspirin 770 mg -1 Citrate caffeine 60 mg inectomy, often cause moderate or severe and more chronic painful skeletal muscle spasm. The principal At the present time, one commercial product, Para symptoms include local pain, tenderness on palpation, 55 fon Forte, a skeletal muscle relaxant formulation con increased muscle consistency and limitation of motion. taining acetaminophen, will be the subject of a hearing For these patients skeletal muscle relaxants alone or in granted by the Commissioner of Food and Drugs on a combination with an analgesic are frequently pre proposal to withdraw approval of its new drug applica scribed. Results of some studies have suggested that a tion sometime in 1985. The Director of the Bureau of formulation of a muscle relaxant and an analgesic pro Drugs of the FDA in a notice published in the Federal vides greater benefit in patients with acute musculoskel Register, 1982, 47 F.R. 22599 concluded that he was etal problems than similar doses of an analgesic alone. unaware of any adequate and well-controlled clinical Table I lists several commercial combinations avail investigation conducted by experts qualified by scien able. A current commercial muscle relaxant formulation tific training and experience ... that demonstrates the is Soma (R) Compound by Carter-Wallace, Inc. which 65 effectiveness of Parafon Forte. The present position of contains 200 mg carisoprodol and 325 mg aspirin. Cari the Commissioner of Food and Drugs is set forth below soprodol is a centrally-acting muscle relaxant that does Federal Register, 1984, 49(200): 48212-482.14): not directly relax tense skeletal muscles in man. Aspirin 4,780,463 3 4 Approval of this NDA will be withdrawn unless Another object of the present invention is to provide there
Load more

Recommended publications
  • CHLORZOXAZONE- Chlorzoxazone Tablet DIRECT RX ------CHLORZOXAZONE
    CHLORZOXAZONE- chlorzoxazone tablet DIRECT RX ---------- CHLORZOXAZONE DESCRIPTION SECTION Chlorzoxazone USP is a centrally acting skeletal muscle relaxant, available as tablets of 500 mg for oral administration. Its chemical name is 5-Chloro-2-benzoxazolinone, and its structural formula is: C7H4CINO2 MW 169.57 Chlorzoxazone USP is a white or practically white, practically odorless, crystalline powder. Chlorzoxazone is slightly soluble in water; sparingly soluble in alcohol, in isopropyl alcohol, and in methanol; soluble in solutions of alkali hydroxides and ammonia. Chlorzoxazone tablets contain the inactive ingredients Docusate Sodium, Lactose (hydrous), Magnesium Stearate, Microcrystalline Cellulose, Pregelatinized Starch, Sodium Benzoate, and Sodium Starch Glycolate. CLINICAL PHARMACOLOGY SECTION Chlorzoxazone is a centrally-acting agent for painful musculoskeletal conditions. Data available from animal experiments as well as human study indicate that chlorzoxazone acts primarily at the level of the spinal cord and subcortical areas of the brain where it inhibits multisynaptic reflex arcs involved in producing and maintaining skeletal muscle spasm of varied etiology. The clinical result is a reduction of the skeletal muscle spasm with relief of pain and increased mobility of the involved muscles. Blood levels of chlorzoxazone can be detected in people during the first 30 minutes and peak levels may be reached, in the majority of the subjects, in about 1 to 2 hours after oral administration of chlorzoxazone. Chlorzoxazone is rapidly metabolized and is excreted in the urine, primarily in a conjugated form as the glucuronide. Less than one percent of a dose of chlorzoxazone is excreted unchanged in the urine in 24 hours. INDICATIONS & USAGE SECTION Chlorzoxazone is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions.
    [Show full text]
  • LORZONE- Chlorzoxazone Tablet Vertical Pharmaceuticals , LLC ---For Painful Musculoskeletal Conditions PRESCRIBING INFOR
    LORZONE- chlorzoxazone tablet Vertical Pharmaceuticals , LLC ---------- For Painful Musculoskeletal Conditions PRESCRIBING INFORMATION DESCRIPTION Each 375 mg Lorzone® tablet contains: chlorzoxazone USP 375 mg. Each 750 mg Lorzone® tablet contains: chlorzoxazone USP 750 mg. Chemical Name: 5-Chloro-2-benzoxazolinone. Structural Formula: Molecular Formula: C7H4CINO2 Molecular Weight: 169.56 Chlorzoxazone USP is a white or practically white, practically odorless, crystalline powder. Chlorzoxazone is slightly soluble in water; sparingly soluble in alcohol, in isopropyl alcohol, and in methanol; soluble in solutions of alkali hydroxides and ammonia. Inactive ingredients: anhydrous lactose, croscarmellose sodium, docusate sodium, magnesium stearate, microcrystalline cellulose, pregelatinized corn starch and sodium benzoate. CLINICAL PHARMACOLOGY Chlorzoxazone is a centrally-acting agent for painful musculoskeletal conditions. Data available from animal experiments as well as human study indicate that chlorzoxazone acts primarily at the level of the spinal cord and subcortical areas of the brain where it inhibits multisynaptic reflex arcs involved in producing and maintaining skeletal muscle spasm of varied etiology. The clinical result is a reduction of the skeletal muscle spasm with relief of pain and increased mobility of the involved muscles. Blood levels of chlorzoxazone can be detected in people during the first 30 minutes and peak levels may be reached, in the majority of the subjects, in about 1 to 2 hours after oral administration of chlorzoxazone. Chlorzoxazone is rapidly metabolized and is excreted in the urine, primarily in a conjugated form as the glucuronide. Less than one percent of a dose of chlorzoxazone is excreted unchanged in the urine in 24 hours. INDICATIONS AND USAGE Lorzone® is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 4,722,938 Sunshine Et Al
    United States Patent (19) 11 Patent Number: 4,722,938 Sunshine et al. (45. Date of Patent: Feb. 2, 1988 (54 METHODS FOR USING 82,717, copy of patent and English translation thereof; MUSCULOSKELETAL RELAXANTS (10/83). Rego, "Mio-Relaxantes No Tratmento Das Lombalgias 75 Inventors: Abraham Sunshine, New York; Agudas E Das Lombo-Ciaticas Recentes'Muscle Re Eugene M. Laska, Larchmont; laxants in the Treatment of Acute Lumbalgias and Re Carole E. Siegel, Mamaroneck, all of cent Lumbo-Sciatica Cases, Acta Reumatologica Por N.Y. tuguesa, II, 2:363-364, (1974), copy of the original and English translation thereof. 73 Assignee: Analgesic Associates, Larchmont, Schror, "Analgetisch-Antiphlogistische Therapie Von N.Y. Schmerzzustanden des Bewegungsapparates'Anal 21 Appl. No.: 815,502 gesic-Antiphlogistic Therapy of Locomotor System Pain), Therapiewoche, 28, 5657-5663, (1978), copy of the (22 Filed: Jan. 2, 1986 original and English translation thereof. Schar, "Medikamentose Behandlung von Lumbois Related U.S. Application Data chialgien'Drug Treatment of the Lumbago-Sciatic Syndrome), Schweiz, Rundschau Med. (Praxis), vol. 68, 63 Continuation of Ser. No. 686,380, Dec. 26, 1984, aban No. 5, pp. 141-142, (Jan. 30, 1979), copy of original doned. article and English translation thereof. 51 Int. Cl....................... A61K 31/19; A61K 31/27 Kolodny and Klipper, "Bone and Joint Diseases in the Elderly', Hospital Practice, pp. 91-101, (Nov. 1976). (52) - O - 514/479; 514/568 Nascimento, "Use of an Association Containing an An 58 Field of Search ................................ 514/568, 479 algesic, a Muscle Relaxant and Vitamin B Complex in (56) References Cited Degenerative Joint Diseases, Extra-Articular Rheu matic Ailments and Traumatic Afflictions', F med, FOREIGN PATENT DOCUMENTS (BR), 83(3):361-363, (1981), original article and English 2121529 12/1971 France.
    [Show full text]
  • Pharmacogenetics of Ketamine Metabolism And
    Pharmacogenetics of Ketamine Metabolism and Immunopharmacology of Ketamine Yibai Li B.HSc. (Hons) Discipline of Pharmacology, School of Medical Sciences, Faculty of Health Sciences, The University of Adelaide September 2014 A thesis submitted for the Degree of PhD (Medicine) Table of contents TABLE OF CONTENTS .............................................................................................. I LIST OF FIGURES ....................................................................................................IV LIST OF TABLES ......................................................................................................IV ABSTRACT ............................................................................................................... V DECLARATION .......................................................................................................VIII ACKNOWLEDGEMENTS ..........................................................................................IX ABBREVIATIONS .....................................................................................................XI CHAPTER 1. INTRODUCTION .................................................................................. 1 1.1 A historical overview of ketamine ........................................................................................ 1 1.2 Structure and Chemistry ....................................................................................................... 3 1.3 Classical analgesic mechanisms of ketamine ...................................................................
    [Show full text]
  • Drug Class Review on Skeletal Muscle Relaxants
    Drug Class Review on Skeletal Muscle Relaxants Final Report Update 2 May 2005 Original Report Date: April 2003 Update 1 Report Date: January 2004 A literature scan of this topic is done periodically The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Roger Chou, MD Kim Peterson, MS Oregon Evidence-based Practice Center Oregon Health & Science University Mark Helfand, MD, MPH, Director Copyright © 2005 by Oregon Health & Science University Portland, Oregon 97201. All rights reserved. Note: A scan of the medical literature relating to the topic is done periodically (see http://www.ohsu.edu/ohsuedu/research/policycenter/DERP/about/methods.cfm for scanning process description). Upon review of the last scan, the Drug Effectiveness Review Project governance group elected not to proceed with another full update of this report. Some portions of the report may not be up to date. Prior versions of this report can be accessed at the DERP website. Final Report Update 2 Drug Effectiveness Review Project TABLE OF CONTENTS Introduction........................................................................................................................4 Scope and
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,636.405 B2 Tamarkin Et Al
    USOO9636405B2 (12) United States Patent (10) Patent No.: US 9,636.405 B2 Tamarkin et al. (45) Date of Patent: May 2, 2017 (54) FOAMABLE VEHICLE AND (56) References Cited PHARMACEUTICAL COMPOSITIONS U.S. PATENT DOCUMENTS THEREOF M (71) Applicant: Foamix Pharmaceuticals Ltd., 1,159,250 A 1 1/1915 Moulton Rehovot (IL) 1,666,684 A 4, 1928 Carstens 1924,972 A 8, 1933 Beckert (72) Inventors: Dov Tamarkin, Maccabim (IL); Doron 2,085,733. A T. 1937 Bird Friedman, Karmei Yosef (IL); Meir 33 A 1683 Sk Eini, Ness Ziona (IL); Alex Besonov, 2,586.287- 4 A 2/1952 AppersonO Rehovot (IL) 2,617,754. A 1 1/1952 Neely 2,767,712 A 10, 1956 Waterman (73) Assignee: EMY PHARMACEUTICALs 2.968,628 A 1/1961 Reed ... Rehovot (IL) 3,004,894. A 10/1961 Johnson et al. (*) Notice: Subject to any disclaimer, the term of this 3,062,715. A 1 1/1962 Reese et al. tent is extended or adiusted under 35 3,067,784. A 12/1962 Gorman pa 3,092.255. A 6/1963 Hohman U.S.C. 154(b) by 37 days. 3,092,555 A 6/1963 Horn 3,141,821 A 7, 1964 Compeau (21) Appl. No.: 13/793,893 3,142,420 A 7/1964 Gawthrop (22) Filed: Mar. 11, 2013 3,144,386 A 8/1964 Brightenback O O 3,149,543 A 9/1964 Naab (65) Prior Publication Data 3,154,075 A 10, 1964 Weckesser US 2013/0189193 A1 Jul 25, 2013 3,178,352.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Topical Treatments of Skin Pain Associated with Hidradenitis Supprurativa
    UC Davis Dermatology Online Journal Title Topical treatments of skin pain: a general review with a focus on hidradenitis suppurativa with topical agents Permalink https://escholarship.org/uc/item/4m57506k Journal Dermatology Online Journal, 20(7) Author Scheinfeld, Noah Publication Date 2014 DOI 10.5070/D3207023131 License https://creativecommons.org/licenses/by-nc-nd/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Volume 20 Number 7 July 2014 Review Topical treatments of skin pain: a general review with a focus on hidradenitis suppurativa with topical agents Noah Scheinfeld MD JD Dermatology Online Journal 20 (7): 3 Assistant Clinical Professor of Dermatology Weil Cornel Medical College Correspondence: Noah Scheinfeld 150 West 55th Street NYC NY 10019 (212) 991-6490 [email protected] Abstract Hidradenitis Supprurativa (HS) is a painful chronic follicular disease. Few papers have addressed pain control for this debilitating condition. Possible topical agents include tricyclic antidepressants, opioids, anticonvulsants, NSAIDs, NMDA receptor antagonists, local anesthetics and other agents. The first line agents for the topical treatment of the cutaneous pain of HS are diclonefac gel 1% and liposomal xylocaine 4% and 5% cream or 5% ointment. The chief advantage of topical xylocaine is that is quick acting i.e. immediate however with a limited duration of effect 1-2 hours. The use of topical ketamine, which blocks n- methyl-D-aspartate receptors in a non-competitive fashion, might be a useful tool for the treatment of HS pain. Topical doxepin, which available in a 5% commercially preparation (Zonalon®) , makes patients drowsy and is not useful for controlling the pain of HS .
    [Show full text]
  • On the Approximation of the Laws of the Member States Relating to Cosmetic Products (76/768/EEC )
    27 . 9 . 76 Official Journal of the European Communities No L 262/169 COUNCIL DIRECTIVE of 27 July 1976 on the approximation of the laws of the Member States relating to cosmetic products (76/768/EEC ) THE COUNCIL OF THE EUROPEAN COMMUNITIES, regards the composition, labelling and packaging of cosmetic products ; Having regard to the Treaty establishing the Euro­ pean Economic Community, and in particular Whereas this Directive relates only to cosmetic prod­ Article 100 thereof, ucts and not to pharmaceutical specialities and medicinal products ; whereas for this purpose it is necessary to define the scope of the Directive by Having regard to the proposal from the Commission, delimiting the field of cosmetics from that of phar­ maceuticals ; whereas this delimitation follows in particular from the detailed definition of cosmetic Having regard to the opinion of the European Parlia­ products, which refers both to their areas of appli­ ment ( 1 ), cation and to the purposes of their use; whereas this Directive is not applicable to the products that fall Having regard to the opinion of the Economic and under the definition of cosmetic product but are Social Committee (2 ), exclusively intended to protect from disease; whereas, moreover, it is advisable to specify that certain prod­ ucts come under this definition, whilst products Whereas the provisions laid down by law, regulation containing substances or preparations intended to be or administrative action in force in the Member ingested, inhaled, injected or implanted in the human States
    [Show full text]
  • San Juan County Adult Drug Court Participant Handbook
    Participant Manual SEVENTH DISTRICT ADULT DRUG COURT MONTICELLO, UTAH Updated January 2018 Subject to Change 1 2 Welcome to the San Juan County Adult Drug Court This Handbook is designed to introduce you to the San Juan County Drug Court program, answer your questions and provide overall information about the Drug Court Program. As a participant, you will be expected to follow the instructions given in Drug Court by the Judge and comply with the treatment plan developed for you by the treatment team. If you are reading this Handbook it means that we are confident that Drug Court will help you to learn how to make successful choices free of the influence of drugs or alcohol. 3 Table of Contents Welcome to the San Juan County Adult Drug Court ...................................................................... 3 Overview ....................................................................................................................................... 6 Drug Court Team ........................................................................................................................... 7 Judge’s Role ........................................................................................................................... 7 San Juan County Attorney’s Role (Prosecutor) ....................................................................... 8 Defense Attorney Role (Your Attorney) ................................................................................... 8 Probation Officer’s Role .........................................................................................................
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • The Effect of Antidepressive Drugs and Some Related Compounds on the Levels of Adenine Nucleotides, Inorganic Phosphate and Phosphocreatine in the Rat Brain by J
    Brit. J. Pharmacol. (1963), 20, 462-470. THE EFFECT OF ANTIDEPRESSIVE DRUGS AND SOME RELATED COMPOUNDS ON THE LEVELS OF ADENINE NUCLEOTIDES, INORGANIC PHOSPHATE AND PHOSPHOCREATINE IN THE RAT BRAIN BY J. J. LEWIS AND G. R. VAN PETTEN From the Experimental Pharmacology Division, Institute of Physiology, University of Glasgow (Received January 11, 1963) The effects upon levels of adenine nucleotides, phosphocreatine and inorganic phosphate of iproniazid, isoniazid, phenelzine, pheniprazine, tranylcypromine, harmine, imipramine, amitriptyline, orphenadrine, diphenhydramine and cocaine have been studied. With the exception of harmine and diphenhydramine, each of these compounds increased the brain level of adenosine triphosphate and, with the exception of imipramine and cocaine, the level of adenosine diphosphate decreased. Harmine had no effect on levels of adenine nucleotides and, in the case of diphenhydramine, the level of adenosine diphosphate increased and the level of adenosine triphosphate tended to decrease. There appears to be a relationship between the ability of the drugs to cause behavioural signs of central nervous stimulation and to produce an increase in the adenosine triphosphate/diphosphate ratio. This effect may be a factor in the action of antidepressive drugs. Many attempts have been made to explain the mechanism of action of anti- depressive drugs on the basis of their ability to inhibit monoamine oxidase, and thereby to increase the effective concentrations in the brain of its substrates, nor- adrenaline and 5-hydroxytryptamine, which have been postulated to act there as transmitters. Major difficulties arise, however, when an attempt is made to correlate the increase in the brain level of a particular amine produced by a drug with its antidepressive activity.
    [Show full text]